Literature DB >> 10404874

Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies.

D M Asher1.   

Abstract

Since 1993, consistent with its statutory responsibility to ensure that regulated products are safe, pure, and free of << extraneous organisms, >> the United States Food and Drug Administration (FDA) has requested that, with certain exceptions, bovine-derived materials from animals born in or residing in countries where bovine spongiform encephalopathy has occurred, should not be used to manufacture products intended for humans. FDA's Center for Biologics Evaluation and Research (CBER) has specifically recommended that serum used to produce biologicals be obtained from sources << certified to be free from contaminants and adventitious agents, such as the agent responsible for the production of Bovine Spongiform Encephalopathy. >> The United States Department of Agriculture (USDA) has prohibited importation of such serum for use in products. FDA staff are aware that bovine blood, including foetal blood, and placental tissues and fluids that might contaminate foetal serum have not been found to contain the infectious agent of BSE, and that those tissues are considered by most authorities to have little risk for transmitting disease to humans or animals. However, studies of BSE have been limited in size and sensitivity, and several experimental studies of scrapie and CJD in rodents found their blood to be infectious. In addition, a recent unpublished study of BSE (requiring confirmation) reported finding infectivity in the bone marrow of cattle. Possible transmission of BSE from cows to calves, although unlikely to constitute a major mode for maintaining the BSE outbreak, has also not been rigorously ruled out. Considering the special nature of biological products, especially of vaccines intended for widespread use in children, it seems prudent for U.S. regulatory authorities to continue current conservative policies that discourage or prohibit the use of bovine serum from countries with BSE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404874

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  11 in total

1.  A plea to reduce or replace fetal bovine serum in cell culture media.

Authors:  Gerhard Gstraunthaler; Toni Lindl; Jan van der Valk
Journal:  Cytotechnology       Date:  2013-08-22       Impact factor: 2.058

2.  Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells.

Authors:  Karen Bieback; Katharina Schallmoser; Harald Klüter; Dirk Strunk
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

Review 3.  Insights into bone marrow-derived mesenchymal stem cells safety for cutaneous repair and regeneration.

Authors:  Y Wu; S Huang; J Enhe; X Fu
Journal:  Int Wound J       Date:  2012-08-30       Impact factor: 3.315

Review 4.  Adult human neural stem cell therapeutics: Current developmental status and prospect.

Authors:  Hyun Nam; Kee-Hang Lee; Do-Hyun Nam; Kyeung Min Joo
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

Review 5.  The evolution of vascular tissue engineering and current state of the art.

Authors:  Marissa Peck; David Gebhart; Nathalie Dusserre; Todd N McAllister; Nicolas L'Heureux
Journal:  Cells Tissues Organs       Date:  2011-10-13       Impact factor: 2.481

6.  Cell manipulation in autologous chondrocyte implantation: from research to cleanroom.

Authors:  Livia Roseti; Marta Serra; Domenico Tigani; Irene Brognara; Annamaria Lopriore; Alessandra Bassi; Pier Maria Fornasari
Journal:  Chir Organi Mov       Date:  2008-05-21

7.  Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components.

Authors:  Natalie Fekete; Mélanie Gadelorge; Daniel Fürst; Caroline Maurer; Julia Dausend; Sandrine Fleury-Cappellesso; Volker Mailänder; Ramin Lotfi; Anita Ignatius; Luc Sensebé; Philippe Bourin; Hubert Schrezenmeier; Markus Thomas Rojewski
Journal:  Cytotherapy       Date:  2012-02-02       Impact factor: 5.414

8.  Kuru: memories of the NIH years.

Authors:  David M Asher
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-11-27       Impact factor: 6.237

Review 9.  Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices.

Authors:  Ratti Ram Sharma; Kathryn Pollock; Allison Hubel; David McKenna
Journal:  Transfusion       Date:  2013-10-16       Impact factor: 3.157

10.  Isolation and characterization of human dental pulp derived stem cells by using media containing low human serum percentage as clinical grade substitutes for bovine serum.

Authors:  Federico Ferro; Renza Spelat; Antonio Paolo Beltrami; Daniela Cesselli; Francesco Curcio
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.